Oncology

Lung Cancer TNM Staging

Simplified NSCLC TNM staging (8th edition IASLC) with 5-year survival estimates.

When to use: Used to stage non-small cell lung cancer (NSCLC) after pathological or clinical assessment of primary tumour size, nodal involvement, and metastatic status. Staging guides treatment decisions and provides prognostic information.

Calculator

T: Primary Tumour

N: Nodal Involvement

M: Distant Metastasis

Fill in all fields to see the result

Formula

Stage I: T1-2 N0 M0 Stage II: T1-2 N1 M0 or T3 N0 M0 Stage III: T3-4 N1 M0, or any T N2-3 M0 Stage IV: any T any N M1

Key Points for NEET PG

NSCLC (80–85%) vs SCLC (15–20%): staging system differs; SCLC uses limited/extensive stage
Stage I–II: surgery (lobectomy); Stage III: chemoradiation ± surgery; Stage IV: systemic therapy
N2 disease (ipsilateral mediastinal) is pivotal; it converts from surgical to non-surgical management
Most common NSCLC: Adenocarcinoma (peripheral) > Squamous cell (central) > Large cell
Pancoast tumour (superior sulcus): T3–T4; presents with Horner syndrome (ptosis, miosis, anhidrosis)

References

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups (8th edition) · Journal of Thoracic Oncology (2016)

For educational purposes only. Not for clinical decision-making without professional oversight.

“Wherever the art of medicine is loved, there is also a love of humanity.” — Hippocrates